Profile data is unavailable for this security.
About the company
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab is a full-length, humanized anti-Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. Its biologics license application (BLA) for ONS-5010 in wet AMD involved three clinical trials, which include NORSE ONE, NORSE TWO and NORSE THREE. The Company sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets.
- Revenue in USD (TTM)0.00
- Net income in USD-159.13m
- Incorporated2015
- Employees24.00
- LocationOutlook Therapeutics Inc111 S. Wood Avenue, Unit #100ISELIN 08830United StatesUSA
- Phone+1 (609) 619-3990
- Websitehttps://outlooktherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Metagenomi Inc | -100.00bn | -100.00bn | 194.06m | 237.00 | -- | 0.7041 | -- | -- | -- | -- | -- | 7.36 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
| Candel Therapeutics Inc | 0.00 | -37.37m | 195.50m | 42.00 | -- | 32.25 | -- | -- | -1.29 | -1.29 | 0.00 | 0.2037 | 0.00 | -- | -- | 0.00 | -75.90 | -- | -93.79 | -- | -- | -- | -- | -- | -- | -38.49 | 0.7674 | -- | -100.00 | -- | -101.87 | -- | -- | -- |
| Coherus Biosciences Inc | 301.87m | -59.29m | 199.62m | 249.00 | -- | -- | -- | 0.6613 | -0.7801 | -0.7801 | 2.86 | -0.7211 | 0.5178 | 3.17 | 1.71 | 986,506.60 | -10.17 | -21.43 | -23.51 | -29.32 | 41.46 | 79.01 | -19.64 | -36.56 | 1.05 | -3.87 | 1.21 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| Trevi Therapeutics Inc | 0.00 | -33.57m | 200.04m | 25.00 | -- | 2.71 | -- | -- | -0.338 | -0.338 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -34.47 | -47.39 | -38.08 | -54.41 | -- | -- | -- | -- | -- | -- | 0.0017 | -- | -- | -- | 0.2984 | -- | -2.81 | -- |
| Lineage Cell Therapeutics Inc | 8.00m | -23.66m | 200.15m | 75.00 | -- | 2.76 | -- | 25.01 | -0.1344 | -0.1344 | 0.0455 | 0.3836 | 0.0722 | -- | 57.16 | 106,706.70 | -21.32 | -19.53 | -24.82 | -22.59 | 91.88 | 89.13 | -295.30 | -370.88 | -- | -- | 0.0018 | -- | -39.16 | 12.39 | 18.22 | -- | -27.16 | -- |
| XBiotech Inc | 0.00 | -30.74m | 200.41m | 92.00 | -- | 0.9574 | -- | -- | -1.01 | -1.01 | 0.00 | 6.87 | 0.00 | -- | -- | 0.00 | -13.08 | 31.88 | -13.68 | 33.27 | -- | -- | -- | 877.30 | -- | -- | 0.0456 | 0.00 | -100.00 | -- | 25.36 | -- | 24.30 | -- |
| Generation Bio Co | 9.96m | -169.06m | 202.25m | 174.00 | -- | 1.53 | -- | 20.30 | -2.56 | -2.56 | 0.1509 | 1.99 | 0.0278 | -- | 10.98 | 57,258.62 | -47.14 | -36.96 | -50.75 | -39.21 | -- | -- | -1,696.87 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
| Ventyx Biosciences Inc | 0.00 | -192.60m | 208.68m | 74.00 | -- | 0.6797 | -- | -- | -3.24 | -3.24 | 0.00 | 4.35 | 0.00 | -- | -- | 0.00 | -53.41 | -- | -55.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.97 | -- | -- | -- |
| P3 Health Partners Inc | 1.35bn | -67.27m | 209.23m | 400.00 | -- | 0.4764 | -- | 0.1547 | -0.5855 | -0.5855 | 11.86 | 1.23 | 1.57 | -- | 11.40 | 3,381,965.00 | -21.31 | -- | -90.11 | -- | 1.59 | 0.1781 | -13.57 | -56.93 | -- | -10.05 | 0.2368 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
| Outlook Therapeutics Inc | 0.00 | -159.13m | 209.48m | 24.00 | -- | -- | -- | -- | -11.48 | -11.48 | 0.00 | -6.10 | 0.00 | -- | -- | 0.00 | -281.52 | -214.69 | -2,060.72 | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -26.75 | -- | -- | -- | -- | 10.70 | -- | -- | -- |
| Renovaro Inc | 0.00 | -53.93m | 212.41m | 11.00 | -- | 1.26 | -- | -- | -0.7661 | -0.7661 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -37.06 | -27.81 | -41.75 | -28.44 | -- | -- | -- | -- | -- | -24.38 | 0.0405 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
| Actinium Pharmaceuticals Inc | 81.00k | -46.45m | 219.80m | 49.00 | -- | 4.95 | -- | 2,713.60 | -1.72 | -1.72 | 0.003 | 1.49 | 0.0009 | -- | -- | 1,653.06 | -48.80 | -46.98 | -53.25 | -52.71 | -- | -- | -57,346.91 | -6,683.95 | -- | -- | 0.0006 | -- | -92.14 | -- | -47.86 | -- | 9.75 | -- |
| Chromadex Corp | 83.17m | -3.53m | 219.82m | 106.00 | -- | 7.55 | -- | 2.64 | -0.047 | -0.047 | 1.11 | 0.3852 | 1.54 | 2.66 | 10.01 | 784,594.30 | -6.54 | -42.11 | -10.08 | -65.14 | 60.98 | 59.68 | -4.24 | -30.64 | 1.88 | -- | 0.0007 | -- | 15.99 | 21.50 | 70.15 | -- | -36.66 | -- |
| Abeona Therapeutics Inc | 3.50m | -76.66m | 222.02m | 84.00 | -- | -- | -- | 63.43 | -3.20 | -3.20 | 0.1461 | -0.3224 | 0.0546 | -- | 2.54 | 41,666.67 | -119.62 | -53.22 | -140.83 | -65.81 | -- | -- | -2,190.26 | -1,894.25 | -- | -- | 1.97 | -- | 147.52 | 3.14 | -24.63 | -- | -55.74 | -- |
| Zura Bio Ltd | 0.00 | -60.18m | 223.11m | 14.00 | -- | 2.50 | -- | -- | -1.63 | -1.63 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -86.77 | -- | -127.21 | -- | -- | -- | -- | -- | -- | -- | 0.021 | -- | -- | -- | -2,050.99 | -- | -- | -- |
| Seres Therapeutics Inc | 126.85m | -82.68m | 224.14m | 233.00 | -- | -- | -- | 1.77 | -0.6062 | -0.6062 | 0.9495 | -0.3945 | 0.4149 | -- | -- | 544,407.80 | -27.04 | -41.51 | -36.82 | -54.13 | -- | -- | -65.18 | -170.14 | 1.25 | -9.21 | 2.41 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
Data as of Jul 22 2024. Currency figures normalised to Outlook Therapeutics Inc's reporting currency: US Dollar USD
29.67%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Tang Capital Management LLCas of 31 Mar 2024 | 1.62m | 6.92% |
| Great Point Partners LLCas of 01 Apr 2024 | 1.48m | 6.32% |
| Armistice Capital LLCas of 17 Jun 2024 | 714.29k | 3.05% |
| Sphera Funds Management Ltd.as of 17 Jun 2024 | 601.05k | 2.57% |
| Caligan Partners LPas of 31 Mar 2024 | 500.00k | 2.14% |
| Velan Capital Investment Management LPas of 31 Mar 2024 | 500.00k | 2.14% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 467.12k | 2.00% |
| Rosalind Advisors, Inc.as of 30 Jun 2024 | 450.00k | 1.92% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 326.45k | 1.40% |
| Schonfeld Strategic Advisors LLCas of 31 Mar 2024 | 285.71k | 1.22% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
